Synucleinopathies: Clinical and Pathological Implications
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The synucleinopathies are a diverse group of neurodegenerative disorders that share a common pathologic lesion composed of aggregates of insoluble alpha-synuclein protein in selectively vulnerable populations of neurons and glia. Growing evidence links the formation of abnormal filamentous aggregates to the onset and progression of clinical symptoms and the degeneration of affected brain regions in neurodegenerative disorders. These disorders may share an enigmatic symmetry, i.e., missense mutations in the gene encoding for the disease protein (alpha-synuclein) cause familial variants of Parkinson disease as well as its hallmark brain lesions, but the same brain lesions also form from the corresponding wild-type brain protein in the more common sporadic varieties of Parkinson disease. It is likely that clarification of this enigmatic symmetry in 1 form of synucleinopathy will have a profound impact on understanding the mechanisms underlying all these disorders. Furthermore, these efforts will likely lead to novel diagnostic and therapeutic strategies in regard to the synucleinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal
Maroteaux, L., Campanelli, J., & Scheller, R. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02804.1988 · Cited by 1,641
(1998) · Europe PMC (PubMed Central) · Cited by 1,594
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.
Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., & Saitoh, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11282 · Cited by 1,480
Clayton, D. F., & George, J. M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01213-7 · Cited by 779
Tu, P., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., & Lee, V. M. ‐. (1998) · Annals of Neurology · doi:10.1002/ana.410440324 · Cited by 686 · cited 2×
“Significantly, aS has been implicated as a major component of the tubulofilamentous inclusions found in oligodendrocytes in multiple system atrophy known as glial cytoplasmic inclusions (GCIs).(2,3,5,6,28) Multiple system atrophy consists of a syndrome complex with parkinsonism and a combination of cerebellar, autonom…”
BackgroundResultSelf-citationAlpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
Hurtig, H. I., Trojanowski, J. Q., Galvin, J., Ewbank, D., Schmidt, M. L., Lee, V. M. Y., Clark, C. M., Glosser, G., Stern, M. B., Gollomp, S. M., et al. (2000) · Neurology · doi:10.1212/wnl.54.10.1916 · Cited by 601
Self-citationProspects for new restorative and neuroprotective treatments in Parkinson's disease
Dunnett, S. B., & Björklund, A. (1999) · Nature · doi:10.1038/399a032 · Cited by 537
Cited by
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
“The brains of all of the incidental cases and of individuals with clinically overt sporadic PD display the presence of -synuclein-immunoreactive LNs and LBs while at the same time being free of intracytoplasmic inclusions related to non-PD -synucleinopathies [35,41].”
BackgroundThe new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
“The intraneuronal inclusion bodies consist mainly of aggregations of a misfolded protein, α-synuclein (Wakabayashi et al. 1992; Spillantini et al. 1997; Dickson 1999; Duda et al. 2000; Giasson et al. 2000; Galvin et al. 2001; Goedert 2001; Jensen and Gai 2001), which is mostly located in both the axon and its terminal…”
BackgroundBraak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
The many faces of α-synuclein: from structure and toxicity to therapeutic target
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3406 · Cited by 1,622
Intrinsically Disordered Proteins in Human Diseases: Introducing the D2Concept
Uversky, V. N., Oldfield, C. J., & Dunker, A. K. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125924 · Cited by 1,410
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Function and structure of inherently disordered proteins
Dunker, A. K., Silman, I., Uversky, V. N., & Sussman, J. L. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2008.10.002 · Cited by 963
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
“All the incidental cases presented with a-SN-immunopositive LNs and/or LBs and were free of other inclusion bodies related to non-PD a-synucleinopathies (3, 15).”
BackgroundDJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
“essential tremor, multiple system atrophy and progressive supranuclear palsy (Galvin et al., 2001; Burn and Lees, 2002).”
BackgroundSeries Introduction: Neurodegeneration: What is it and where are we?
Przedborski, S., Vila, M., & Jackson-Lewis, V. R. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17522 · Cited by 584
Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation
Uversky, V. N. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04764.x · Cited by 567
Invited Article: Nervous system pathology in sporadic Parkinson disease
Braak, H., & Del Tredici, K. (2008) · Neurology · doi:10.1212/01.wnl.0000312279.49272.9f · Cited by 538
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Sudhof, T. C., & Rizo, J. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005637 · Cited by 510
Orimo, S., Uchihara, T., Nakamura, A., Mori, F., Kakita, A., Wakabayashi, K., & Takahashi, H. (2008) · Brain · doi:10.1093/brain/awm302 · Cited by 462
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein
Cole, N. B., Murphy, D. D., Grider, T., Rueter, S., Brasaemle, D., & Nussbaum, R. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108414200 · Cited by 430
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Groveman, B. R., Orrù, C. D., Hughson, A. G., Raymond, L. D., Zanusso, G., Ghetti, B., Campbell, K. J., Safar, J., Galasko, D., & Caughey, B. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0508-2 · Cited by 421
Protein composition of the intranuclear inclusions of FXTAS
Iwahashi, C. K., Yasui, D. H., An, H.-J., Greco, C. M., Tassone, F., Nannen, K., Babineau, B., Lebrilla, C. B., Hagerman, R. J., & Hagerman, P. J. (2006) · Brain · doi:10.1093/brain/awh650 · Cited by 359
Neuropathological spectrum of synucleinopathies
Jellinger, K. A. (2003) · Movement Disorders · doi:10.1002/mds.10557 · Cited by 340
Lewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy
Tanik, S. A., Schultheiss, C. E., Volpicelli-Daley, L. A., Brunden, K. R., & Lee, V. M. Y. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457408 · Cited by 326
“Synucleinopathies are a family of neurodegenerative diseases characterized by cytoplasmic aggregates of the protein -synuclein ( -syn)(2) and include Parkinson disease (PD), PD with dementia, dementia with Lewy bodies, and multiple system atrophy (1, 2).”
BackgroundSelf-citationHypoxia and brain aging: Neurodegeneration or neuroprotection?
Burtscher, J., Mallet, R. T., Burtscher, M., & Millet, G. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101343 · Cited by 324
Games, D., Valera, E., Spencer, B., Rockenstein, E., Mante, M., Adame, A., Patrick, C., Ubhi, K., Nuber, S., Sacayon, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5314-13.2014 · Cited by 322
Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Uversky, V., & Eliezer, D. (2009) · Current Protein & Peptide Science · doi:10.2174/138920309789351921 · Cited by 322
Sardi, S. P., Clarke, J., Kinnecom, C., Tamsett, T. J., Li, L., Stanek, L. M., Passini, M. A., Grabowski, G. A., Schlossmacher, M. G., Sidman, R. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108197108 · Cited by 319
Induction of Autophagy in Axonal Dystrophy and Degeneration
Wang, Q. J., Ding, Y., Kohtz, S., Mizushima, N., Cristea, I. M., Rout, M. P., Chait, B. T., Zhong, Y., Heintz, N., & Yue, Z. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2261-06.2006 · Cited by 308
SNCA variants are associated with increased risk for multiple system atrophy
Scholz, S. W., Houlden, H., Schulte, C., Sharma, M., Li, A., Berg, D., Melchers, A., Paudel, R., Gibbs, J. R., Simon‐Sanchez, J., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21685 · Cited by 281
Unfoldomics of human diseases: linking protein intrinsic disorder with diseases
Uversky, V. N., Oldfield, C. J., Midic, U., Xie, H., Xue, B., Vucetic, S., Iakoucheva, L. M., Obradovic, Z., & Dunker, A. K. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-s1-s7 · Cited by 281
Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins
Perrin, R. J., Woods, W. S., Clayton, D. F., & George, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105022200 · Cited by 279
Clinical phenotype of Parkinson disease dementia
Galvin, J. E., Pollack, J., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000242630.52203.8f · Cited by 265
Self-citationPart II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
Dev, K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 263
Interleukin-1 mediates Alzheimer and Lewy body pathologies
Griffin, W. S. T., Liu, L., Li, Y., Mrak, R. E., & Barger, S. W. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-5 · Cited by 262
Zhu, J., Guo, F., Shelburne, J., Watkins, S., & Chu, C. T. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00478.x · Cited by 255
Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease
Williams, M. M., Xiong, C., Morris, J. C., & Galvin, J. E. (2006) · Neurology · doi:10.1212/01.wnl.0000247041.63081.98 · Cited by 239
Self-citationα‐Synuclein produces a long‐lasting increase in neurotransmitter release
Liu, S., Ninan, I., Antonova, I., Battaglia, F., Trinchese, F., Narasanna, A., Kolodilov, N., Dauer, W., Hawkins, R. D., & Arancio, O. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600451 · Cited by 198
Could a loss of α‐synuclein function put dopaminergic neurons at risk?
Perez, R. G., & Hastings, T. G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02423.x · Cited by 133
General aspects of neurodegeneration
Jellinger, K. A. (2003) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-0643-3_7 · Cited by 126
Iba, M., Kim, C., Sallin, M., Kwon, S., Verma, A., Overk, C., Rissman, R. A., Sen, R., Sen, J. M., & Masliah, E. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01888-0 · Cited by 120
“…of the aging population are a group of neurodegenerative disorders with progressive α -synuclein ( α -syn) accumulation in neuronal and non-neuronal cells of cortical [1, 2] and subcortical brain regions with clinical presentations of dementia, parkinsonism, and autonomic dysfunction [3 – 5].”
RetractedUltrasound targeted CNS gene delivery for Parkinson's disease treatment
Fan, C.-H., Lin, C.-Y., Liu, H.-L., & Yeh, C.-K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.004 · Cited by 97
Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H., Zweckstetter, M., Outeiro, T. F., & Braus, G. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.361865 · Cited by 81
Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: Similarities and differences
Iodice, V., Low, D. A., Vichayanrat, E., & Mathias, C. J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.014 · Cited by 81
Ninkina, N., Papachroni, K., Robertson, D. C., Schmidt, O., Delaney, L., O'Neill, F., Court, F., Rosenthal, A., Fleetwood-Walker, S. M., Davies, A. M., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8233-8245.2003 · Cited by 75
“Several neurodegenerative diseases have been recently coalesced into a distinct group named synucleinopathies (12, 16, 20, 53).”
BackgroundThe muscle protein dysferlin accumulates in the Alzheimer brain
Galvin, J. E., Palamand, D., Strider, J., Milone, M., & Pestronk, A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0147-8 · Cited by 36
“neuroWbrillary tangles and the presynaptic protein synuclein [13] in the form of Lewy bodies.”
BackgroundSelf-citationStaging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions
Archer, T., Kostrzewa, R. M., Beninger, R. J., & Palomo, T. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9190-2 · Cited by 34
“Notably, multiple system atrophy has been termed collectively as an a-synucleinopathy (Galvin et al. 2001; Kramer and Schulz-Schaeffer 2007).”
Background
Metadata
- Authors
- Galvin, J. E., Lee, V. M.-Y., & Trojanowski, J. Q.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2001-02-01
- Volume
- 58
- Issue
- 2
- Pages
- 186
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2037948191
- Cited by
- 466
- References
- 31
- FWCI
- 20.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.